Executive order to raise drug price transparency is signed by DeSantis
"I think it's going to be very, very meaningful."
Gov.
Gov.
The point of the executive order is to ultimately lower the price of prescription drugs. DeSantis said. He said that with the rise in food and gas costs, addressing the price of pharmaceuticals is one area he could "make a difference."
"This executive order is really probably the first time
The order would help make pharmacy benefit managers, third-party administrators of prescription drug programs, accountable when managing prescription drug benefits for insurance companies.
"
The order directs all executive agencies to include the following in all future contracts with PBMs:
Prohibit spread pricing
Prohibit reimbursement claw backs
Include data transparency and reporting requirements
Review all rebates, payments and relationships between pharmacies, insurers and manufacturers
Amend all current contracts they can with the same provisions
In a news release sent Friday, Jackson applauded DeSantis on the executive order.
"We are encouraged by this latest development – which follows the passage of House Bill 357 — and the governor's continued commitment on this critical issue facing so many Floridians and their families," Jackson said.
House Bill 357, which went into effect
"We're going to use the executive order as our baseline and we're going to look for more ways to ensure that we are saving taxpayers money and we are ensuring that independent and small pharmacies can serve not only the Medicaid population, but all members of this community without going out of business at the hands of PBMs."
The biggest hurdle though, according to DeSantis and Marstiller, is the
The executive order isn't the only thing the state has done to try and lower prescription drug prices, according to DeSantis. The state's Canadian Prescription Drug Importation Program has been under review by the FDA for nearly 600 days.
This program, if approved, would allow prescriptions drugs to be imported to
ACHA filed a Freedom of Information Act to find out why the program has been stalled.
DeSantis pointed out that while the FDA was quick to approve COVID-19 vaccines for children, and the import of baby formula, the agency has taken its time when it comes to
"It's interesting when you look at the FDA dragging their feet on what we're trying to do, which is buy cheaper drugs," DeSantis said.
"I think it's going to be very, very meaningful."
Gov.


Louisiana Extends Ida Mediation Program Through End of 2022
Musk abandons deal to buy Twitter; company says it will sue
Advisor News
- How advisors can prepare clients for an uncertain retirement landscape
- Investors aren’t waiting out uncertainty
- Transamerica and Advo(k)ate Advisors launch pooled employer plan
- ‘I wish I’d met him sooner:’ Karlan Tucker remembered for integrity, faith
- Why women must be more engaged in investing
More Advisor NewsAnnuity News
- Lumos Insurance introduces the Immediate Care Plan to help families fund long-term care
- NAIC regulators begin consensus phase on annuity illustration overhaul
- AM Best Revises Outlooks to Negative for Subsidiaries of Group 1001 Insurance Holdings, LLC
- Market-value adjusted annuities: Key considerations for advisors
- Private equity’s next play in insurance
More Annuity NewsHealth/Employee Benefits News
- 76% of Gen Z and 63% of millennials turn to AI for first line of primary healthcare
- Oregonians face health insurance premium hikes
- Federal Medicaid cuts threaten Va.
- Editorial: Passing it on
- New York made $21.6M in improper Medicaid payments
More Health/Employee Benefits NewsLife Insurance News
- Supporting small businesses starts with smarter benefits conversations
- Judge again tosses Penn Mutual whole life lawsuit alleging tax scam
- Declined by a machine? The end of the unexplainable no
- AM Best Revises Outlooks to Negative for Subsidiaries of Group 1001 Insurance Holdings, LLC
- Court sides with Ameritas in denying $4M STOLI payout to Wells Fargo
More Life Insurance News